Dr. Novack cited in New York Times article on safety of ophthalmic medications

Dr. Novack was cited in an article in the New York Times on 4 April 2024 regarding the safety of ophthalmic medications. He noted that eye-care products have a higher risk of health harm because they’re applied directly to the eye. Also, that manufacturing and storing these products has to maintain sterility and stability.

Unintended consequences of off-label use

The American Academy of Ophthalmology reported (June 2021) a shortage of bevacizumab as used off-label, aliquoted, for ophthalmic indications in the U.S. The issue surrounding off-label and compounding pharmacy use, particularly with this class of products, were discussed in a recent editorial by Dr. Novack…